| 000 | 01812 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513133936.0 | ||
| 264 | 0 | _c19980225 | |
| 008 | 199802s 0 0 eng d | ||
| 022 | _a1387-2273 | ||
| 024 | 7 |
_a10.1016/s0378-4347(97)00431-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKim, H K | |
| 245 | 0 | 0 |
_aHigh-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. _h[electronic resource] |
| 260 |
_bJournal of chromatography. B, Biomedical sciences and applications _cDec 1997 |
||
| 300 |
_a225-33 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
| 650 | 0 | 4 |
_aChromatography, High Pressure Liquid _xmethods |
| 650 | 0 | 4 | _aCircadian Rhythm |
| 650 | 0 | 4 |
_aDacarbazine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 | _aFreezing |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 | _aOsmolar Concentration |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aSpectrophotometry, Ultraviolet |
| 650 | 0 | 4 | _aTemozolomide |
| 650 | 0 | 4 | _aTemperature |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aLin, C C | |
| 700 | 1 | _aParker, D | |
| 700 | 1 | _aVeals, J | |
| 700 | 1 | _aLim, J | |
| 700 | 1 | _aLikhari, P | |
| 700 | 1 | _aStatkevich, P | |
| 700 | 1 | _aMarco, A | |
| 700 | 1 | _aNomeir, A A | |
| 773 | 0 |
_tJournal of chromatography. B, Biomedical sciences and applications _gvol. 703 _gno. 1-2 _gp. 225-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0378-4347(97)00431-3 _zAvailable from publisher's website |
| 999 |
_c9417206 _d9417206 |
||